Biomarker research for gastric cancer with proteomics and pathway analysis

• Project/Area Number: 26460949
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Gastroenterology
• Research Institution: Keio University
• Principal Investigator: TAKAISHI HIROMASA 慶應義塾大学, 医学部(信濃町), 准教授 (80286468)
• Co-Investigator(Kenkyū-buntansha): 船越 信介 慶應義塾大学, 医学部(信濃町), 講師(非常勤) (20297352) ; 足立 雅之 慶應義塾大学, 医学部(信濃町), 助教 (70338028) ; 須河 恭敬 慶應義塾大学, 医学部(信濃町), 助教 (80772566)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000); Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000); Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 胃癌 / バイオマーカー / sulfasaradine / HER2 / 胃がん / 抗がん剤 / 化学療法 / CD44 / 胃癌バイオマーカー

Outline of Final Research Achievements

We tried to elucidate unknown biological characteristics in gastric cancer, and explore novel biomarker to predict drug sensitivity through the comprehensive genetic and biological analyses.
We found correlation between expression level of CD44v8-10 and sensitivity of sulfasarazine in cell lines of gastric cancer. We currently analyze biomarkers to predict efficacy of trastuzumab, anti-HER2 antibody, in patients with HER2 positive gastric cancer.